Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.

ABSTRACT: Hepatocellular carcinoma (HCC) is an aggressive primary liver neoplasm that, according to tumor stage, can be treated with resection, transplantation, locoregional treatment options, or systemic therapy. Although interventions only in early-stage disease can offer complete tumor regression, systemic therapy in advanced disease can significantly prolong overall survival, according to pub lished clinical trials. The emergence of immunotherapy in the field of cancer therapy has had a positive impact on patients with HCC, resulting in atezolizumab-bevacizumab currently being the first-line option for treatment of advanced HCC. In light of this, application of immunotherapy in the preoperative process could increase the number of patients fulfilling the criteria for liver transplantation (LT).

SUBMITTER: Ouranos K 

PROVIDER: S-EPMC9693898 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature